ArticleHaemophilia : the official journal of the World Federation of Hemophilia
Use of the Multidimensional Haemophilia Pain Questionnaire (MHPQ) in Patients With Severe Haemophilia A Treated With Emicizumab: A Pilot Cross-Sectional, Single-Centre Study.
Article in Haemophilia : the official journal of the World Federation of Hemophilia. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDespite effective bleed prevention with Emicizumab, pain remains a relevant clinical burden in adults with severe haemophilia A (sHA). A multidimensional assessment is needed to better characterize contemporary haemophilia-related pain.
objectiveTo evaluate the prevalence, characteristics, and functional impact of pain in adults with sHA receiving Emicizumab prophylaxis using the Multidimensional Haemophilia Pain Questionnaire (MHPQ).
methodsIn this single-centre, cross-sectional pilot study, 27 adults with sHA on Emicizumab prophylaxis completed the MHPQ. Pain localization, frequency, triggering factors, intensity, and interference across life domains were assessed descriptively.
resultsLifetime haemophilia-related pain was reported by 85.2% of participants, and 77.8% experienced pain within the previous 12 months. Pain most frequently involved ankles (52.4%), knees (52.4%), and elbows (28.6%). All patients with recent pain reported pain during bleeding episodes; however, movement-related triggers, including accidental movements (66.7%) and physical activity (54.2%), were also common. Pain intensity was generally mild-to-moderate, with the highest median scores observed after accidental movements (median 4, IQR 2-6). Pain interfered predominantly with general activity (71.4%), walking ability (66.7%), mood (61.9%), and enjoyment of life (61.9%). Arthropathy was documented in 70.4% of patients.
conclusionsIn the non-factor prophylaxis era, pain remains prevalent and functionally relevant in adults with sHA despite effective bleed control. These findings suggest that haemophilia-related pain is not exclusively bleeding-driven and highlight the importance of structured, multidimensional pain assessment in routine haemophilia care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.